相关实验视频
Updated: May 21, 2025
08:53
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
Published on: August 31, 2016
15.2K
对比并发症指数,预测小儿血造干细胞移植后的生存率,用于非恶性疾病
Roos Lotte Alexandra Bukman1, Anne B Verbeek1, Arjan C Lankester1
1Department of Pediatrics, Pediatric Stem Cell Transplantation Program, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.
Pediatric blood & cancer
|March 19, 2025
概括
青年非恶性造血干细胞移植并发症指数 (ynHCT-CI) 最好预测儿科非恶性 HCT 的结果. 该指数可以改善风险评估,并指导这些年轻患者的临床管理.
科学领域:
- 儿科血液学 儿科血液学
- 移植医学 移植医学
- 临床风险评估临床风险评估
背景情况:
- 造血干细胞移植 (HCT) 为儿科血液学和免疫学疾病提供治疗潜力.
- 治疗相关的发病率和死亡率仍然是HCT后的重大问题.
- 现有的并发症指数被用来预测儿科HCT的并发症.
研究的目的:
- 为了比较四个并发症指数在儿科非恶性HCT后预测发病率和死亡率的准确性.
- 确定该患者群体中风险分层的最有效指数.
主要方法:
- 在2010年至2022年期间对308个儿科全基性非恶性HCT进行分析.
- 评估了四个并发症指数:HCT-CI,ynHCT-CI,简化的ynHCT-CI和SCI.
- 主要结局:整体存活时间 (OS). 二级结局:无GvHD,无事件生存期 (EFS).
- 接收器运营商特征曲线下的面积 (AUC) 为每个指数和结果计算在多个时间点.
主要成果:
- 青年非恶性HCT-CI (ynHCT-CI) 和其简化版本显示出对整体存活 (OS) 的优异区分能力.
- 在预测无GvHD,无事件生存期 (EFS) 方面,ynHCT-CI表现最好.
- 在移植后的100天内,yinHCT-CI显著优于HCT-CI (p=0.045).
结论:
- ynHCT-CI是对儿科非恶性HCT的结果最准确的预测指标.
- 该研究建议将ynHCT-CI纳入该队列的未来临床管理指南.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
110
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
110
01:22Bone Marrow Sampling and Transplants
268
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
268
01:21Cancer Survival Analysis
315
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
315
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
01:24Kaplan-Meier Approach
71
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
71